RS62914B1 - Izoform selektivni inhibitori tgfbeta1 i njihova upotreba - Google Patents
Izoform selektivni inhibitori tgfbeta1 i njihova upotrebaInfo
- Publication number
- RS62914B1 RS62914B1 RS20220099A RSP20220099A RS62914B1 RS 62914 B1 RS62914 B1 RS 62914B1 RS 20220099 A RS20220099 A RS 20220099A RS P20220099 A RSP20220099 A RS P20220099A RS 62914 B1 RS62914 B1 RS 62914B1
- Authority
- RS
- Serbia
- Prior art keywords
- tgfbeta1
- inhibitors
- isoform selective
- isoform
- selective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862696774P | 2018-07-11 | 2018-07-11 | |
US201862696752P | 2018-07-11 | 2018-07-11 | |
US201862718196P | 2018-08-13 | 2018-08-13 | |
US201862722081P | 2018-08-23 | 2018-08-23 | |
US201862737534P | 2018-09-27 | 2018-09-27 | |
US201862758180P | 2018-11-09 | 2018-11-09 | |
US201862757917P | 2018-11-09 | 2018-11-09 | |
US201962810263P | 2019-02-25 | 2019-02-25 | |
US201962827552P | 2019-04-01 | 2019-04-01 | |
EP19185896.8A EP3677278B1 (en) | 2018-07-11 | 2019-07-11 | Isoform selective tgfbeta1 inhibitors and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
RS62914B1 true RS62914B1 (sr) | 2022-03-31 |
Family
ID=67437706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20220099A RS62914B1 (sr) | 2018-07-11 | 2019-07-11 | Izoform selektivni inhibitori tgfbeta1 i njihova upotreba |
Country Status (13)
Country | Link |
---|---|
US (2) | US11130803B2 (sr) |
EP (2) | EP4019046A1 (sr) |
CY (1) | CY1125076T1 (sr) |
DK (1) | DK3677278T3 (sr) |
ES (1) | ES2905160T3 (sr) |
HR (1) | HRP20212034T1 (sr) |
HU (1) | HUE056501T2 (sr) |
LT (1) | LT3677278T (sr) |
MA (1) | MA52165A (sr) |
PL (1) | PL3677278T3 (sr) |
PT (1) | PT3677278T (sr) |
RS (1) | RS62914B1 (sr) |
SI (1) | SI3677278T1 (sr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3169626A1 (en) | 2020-03-19 | 2021-09-23 | Genentech, Inc. | Isoform-selective anti-tgf-beta antibodies and methods of use |
CN114645042A (zh) * | 2020-12-18 | 2022-06-21 | 中国食品药品检定研究院 | 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法 |
WO2022256723A2 (en) * | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
IL312489A (en) * | 2021-11-01 | 2024-07-01 | Genzyme Corp | Treatment of defective bone formation |
CN114236137A (zh) * | 2021-12-17 | 2022-03-25 | 中山大学·深圳 | 一种转化生长因子β的体外检测试剂盒及其应用 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
US6015884A (en) | 1996-03-28 | 2000-01-18 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
PE20020132A1 (es) | 2000-06-29 | 2002-03-04 | Abbott Lab | Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos |
EP1674480A4 (en) | 2003-09-04 | 2007-06-20 | Riken | ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION |
ES2905923T3 (es) | 2005-02-08 | 2022-04-12 | Genzyme Corp | Anticuerpos de TGFbeta |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
US9109026B2 (en) | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
AU2012339722B2 (en) | 2011-11-14 | 2017-09-14 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A |
AU2013341353B2 (en) | 2012-11-06 | 2017-03-16 | Children's Medical Center Corporation | Compositions and methods for modulating cell signaling |
SG10201800800YA (en) | 2013-05-06 | 2018-03-28 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
EP3139957A4 (en) | 2014-05-06 | 2018-04-25 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
US10723793B2 (en) | 2015-06-12 | 2020-07-28 | Ludwig Institute For Cancer Research, Ltd. | TGF-β3 specific antibodies and methods and uses thereof |
JP2018527903A (ja) | 2015-07-22 | 2018-09-27 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | Gdf11結合タンパク質およびその使用 |
KR20230155021A (ko) | 2015-09-15 | 2023-11-09 | 스칼러 락, 인크. | 항-프로/잠재성-미오스타틴 항체 및 그의 용도 |
JP2019509737A (ja) | 2016-03-11 | 2019-04-11 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | TGFβ1結合性免疫グロブリンおよびその使用 |
JP7128801B2 (ja) | 2016-07-14 | 2022-08-31 | スカラー ロック インコーポレイテッド | Tgfb抗体、方法、及び使用 |
CN117398457A (zh) | 2017-01-06 | 2024-01-16 | 供石公司 | 亚型特异性、背景许可性TGFβ1抑制剂及其用途 |
WO2019023661A1 (en) | 2017-07-28 | 2019-01-31 | Scholar Rock, Inc. | SPECIFIC INHIBITORS OF TGF-BETA 1 LTBP COMPLEX AND USES THEREOF |
CA3105988A1 (en) | 2018-07-11 | 2020-01-16 | Abhishek Datta | High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof |
EP3820896A1 (en) | 2018-07-11 | 2021-05-19 | Scholar Rock, Inc. | TGFbeta1 INHIBITORS AND USE THEREOF |
-
2019
- 2019-07-11 RS RS20220099A patent/RS62914B1/sr unknown
- 2019-07-11 EP EP21206768.0A patent/EP4019046A1/en active Pending
- 2019-07-11 DK DK19185896.8T patent/DK3677278T3/da active
- 2019-07-11 HR HRP20212034TT patent/HRP20212034T1/hr unknown
- 2019-07-11 US US16/509,068 patent/US11130803B2/en active Active
- 2019-07-11 LT LTEP19185896.8T patent/LT3677278T/lt unknown
- 2019-07-11 HU HUE19185896A patent/HUE056501T2/hu unknown
- 2019-07-11 PT PT191858968T patent/PT3677278T/pt unknown
- 2019-07-11 EP EP19185896.8A patent/EP3677278B1/en active Active
- 2019-07-11 MA MA052165A patent/MA52165A/fr unknown
- 2019-07-11 SI SI201930143T patent/SI3677278T1/sl unknown
- 2019-07-11 PL PL19185896T patent/PL3677278T3/pl unknown
- 2019-07-11 ES ES19185896T patent/ES2905160T3/es active Active
-
2021
- 2021-08-19 US US17/406,400 patent/US20220064275A1/en active Pending
-
2022
- 2022-01-28 CY CY20221100075T patent/CY1125076T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US11130803B2 (en) | 2021-09-28 |
SI3677278T1 (sl) | 2022-01-31 |
MA52165A (fr) | 2021-06-02 |
US20220064275A1 (en) | 2022-03-03 |
US20200079840A1 (en) | 2020-03-12 |
DK3677278T3 (da) | 2022-01-10 |
HUE056501T2 (hu) | 2022-02-28 |
HRP20212034T1 (hr) | 2022-04-01 |
LT3677278T (lt) | 2022-01-10 |
ES2905160T3 (es) | 2022-04-07 |
EP3677278B1 (en) | 2021-11-10 |
PT3677278T (pt) | 2022-02-03 |
CY1125076T1 (el) | 2023-06-09 |
PL3677278T3 (pl) | 2022-02-28 |
EP3677278A1 (en) | 2020-07-08 |
EP4019046A1 (en) | 2022-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267790A (en) | Isoform-specific, context-permissive tgfbeta1 inhibitors and their use | |
IL282487A (en) | TYK2 inhibitors and their use | |
LT3677278T (lt) | Izoformoms selektyvūs tgfbeta1 inhibitoriai ir jų panaudojimas | |
ZA202002172B (en) | Pde9 inhibitor and use thereof | |
IL283409A (en) | tyk2 inhibitors and uses thereof | |
IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
IL277794A (en) | ATF6 inhibitors and uses thereof | |
GB202107039D0 (en) | PFKFB3 inhibitors and their uses | |
IL282090A (en) | tyk2 inhibitors and uses thereof | |
IL276711A (en) | Arginase inhibitors and methods of using them | |
EP3572400C0 (en) | EZH2 INHIBITOR AND ITS USE | |
IL282350A (en) | Bernani-RGMC inhibitors and their use | |
HUE063120T2 (hu) | LRRC33-inhibitorok és alkalmazásuk | |
IL274504A (en) | 2ACSS inhibitors and methods of their use | |
IL280924A (en) | Arginase inhibitors and methods of using them | |
ZA202102192B (en) | Fgfr4 inhibitor and use thereof | |
IL292198A (en) | Tim-3 inhibitors and their uses | |
IL279276A (en) | ERK inhibitor and use thereof | |
GB2584797B (en) | Measuring device and method | |
IL283106A (en) | erk inhibitors and their uses | |
EP3816158C0 (en) | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS IDH1 INHIBITORS | |
GB201908884D0 (en) | Inhibitors and use | |
IL274964A (en) | Anti-chymase aptamer and its use | |
HK1253249A1 (zh) | 新的5型磷酸二酯酶抑制劑及其應用 |